About: Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Creator	Barlow, Ashley Barlow, Brooke Claassen, Cassidy Heavner, Jason Heavner, Mojdeh Landolf, Kaitlin Yan, Siu Yeung, Amy
Source	Medline; PMC
abstract	The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID‐19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacologic management of patients with COVID‐19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immunomodulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS‐CoV‐2. Critically ill patients with COVID‐19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID‐19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.1002/phar.2398
bibo:pmid	32259313
has license	no-cc
sha1sum (hex)	a19741bbf21dee9c3e331b1e8542190f8a6c1649
schema:url	https://doi.org/10.1002/phar.2398
resource representing a document's title	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
has PubMed Central identifier	PMC7262196
has PubMed identifier	32259313
schema:publication	Pharmacotherapy
resource representing a document's body	covid:a19741bbf21dee9c3e331b1e8542190f8a6c1649#body_text
is schema:about of	named entity 'Pharmacotherapy' named entity 'nitazoxanide' named entity 'remdesivir' named entity 'antiinflammatory' named entity 'IFN-a' named entity 'acute generalized exanthematous pustulosis' named entity 'dosage form' named entity 'ICU' named entity 'chloroquine' named entity 'therapeutic index' named entity 'lung' named entity 'nausea and vomiting' named entity 'metallic taste' named entity 'Nelfinavir' named entity 'cardiomyopathy' named entity 'ACE2' named entity 'purine nucleoside' named entity 'multiple sclerosis' named entity 'abdominal pain' named entity 'septic shock' named entity 'cardiac disease' named entity 'pyruvate' named entity 'lung' named entity 'neutropenia' named entity 'Baricitinib' named entity 'ribavirin' named entity 'HIV' named entity 'life-threatening' named entity 'maintenance dose' named entity 'hemoglobin' named entity 'hemolytic anemia' named entity 'COVID-19' named entity 'antiviral effect' named entity 'RNA synthesis' named entity 'tocilizumab' named entity 'SARS outbreak' named entity 'influenza-like illness' named entity 'COVID' named entity 'enteral' named entity 'subcutaneously' named entity 'electrocardiogram' named entity 'lipids' named entity 'RNA' named entity 'SARS-CoV-2' named entity 'chloroquine' named entity 'supportive care' named entity 'lyophilized' named entity 'simvastatin' named entity 'Interferon' named entity 'COVID-19' named entity 'NIOSH' named entity 'virus' named entity 'viremia' named entity 'COVID' named entity 'standard of care' named entity 'chymotrypsin' named entity 'geriatric' named entity 'polyprotein' named entity 'rheumatoid arthritis' named entity 'diarrhea' named entity 'corticosteroids' named entity 'respiratory syncytial virus' named entity 'RNA' named entity 'murine coronavirus' named entity 'macaque' named entity 'Chloroquine' named entity 'clinical characteristics' named entity 'plasma' named entity 'interferon' named entity 'canine coronavirus' named entity 'methylprednisolone' named entity 'SARS-CoV-2' named entity 'ritonavir' named entity 'vomiting'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software